NCT00664677View on ClinicalTrials.gov

Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions
LeukemiasAcute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)Adult T Cell Leukemia (ATL)Chronic Myeloid Leukemia (CML-BP)Chronic Lymphocytic Leukemia (CLL)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)
Interventions
DRUG

Terameprocol (EM-1421)

Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.

Trial Locations (1)

27599

UNC, Lineberger Comprehensive Cancer Center, Chapel Hill

Sponsors
All Listed Sponsors
lead

Erimos Pharmaceuticals

INDUSTRY

NCT00664677 - Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Biotech Hunter | Biotech Hunter